Neurostimulation for tear production
Authors:
- 1 September 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 30 (5) , 386-394
Abstract
Dry eye disease (DED) is a chronic multifactorial disease that affects millions of people worldwide. Despite ongoing research, treatment for DED remains a challenge. Neurostimulation for tear production is a rapidly evolving field that culminated in the development of the intranasal tear neurostimulator (ITN). In this article, we review the neuroanatomy and pathophysiology of tear production and the evolution of neurostimulation for the treatment of DED. The ITN was approved for commercial use in April 2017. This innovation stemmed from the success of lacrimal nerve and anterior ethmoid nerve stimulation animal studies. Since then, numerous pilot studies and multicenter randomized controlled trials demonstrate increased aqueous tear production, improved DED-related symptoms, and device safety. Recent studies also report the positive effects of intranasal stimulation on mucin and lipid secretion. Neurostimulation for enhanced tear production is a promising new treatment option for DED. Stimulation of the lacrimal nerve and anterior ethmoid nerve both effectively increase tear volume. The ITN is a noninvasive device that effectively increases aqueous tear volume and may improve tear composition, including mucin and lipid concentrations. Further studies are needed to determine proper patient selection and the long-term efficacy of neurostimulation for DED.Keywords
This publication has 26 references indexed in Scilit:
- Electronic enhancement of tear secretionJournal of Neural Engineering, 2015
- Neurostimulation of the Lacrimal Nerve for Enhanced Tear ProductionOphthalmic Plastic & Reconstructive Surgery, 2015
- The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Anatomy, Physiology, and Pathophysiology of the Meibomian GlandInvestigative Ophthalmology & Visual Science, 2011
- Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007)The Ocular Surface, 2007
- Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eyeExperimental Eye Research, 2006
- Phase III Safety Evaluation of Cyclosporine 0.1% Ophthalmic Emulsion Administered Twice Daily to Dry Eye Disease Patients for Up to 3 YearsOphthalmology, 2005
- Experimental Dry Eye Stimulates Production of Inflammatory Cytokines and MMP-9 and Activates MAPK Signaling Pathways on the Ocular SurfaceInvestigative Ophthalmology & Visual Science, 2004
- Inflammation in Dry EyeThe Ocular Surface, 2004
- Quantitative Measurements of the Nasolacrimal ReflexActa Oto-Laryngologica, 1959
- LE RÉFLEXE NASO‐OCULAIRE VASODILATAOIRE ET RA VALEUR DIAGNOSTIQUEActa Psychiatrica Scandinavica, 1927